
The treatment of castration‐resistant prostate cancer (CRPC) is a urological issue. Recent studies have revealed cancer promotion via the C5a–C5a receptor (C5aR) system. To establish a new therapeutic target for CRPC, we investigated an association of the system with CRPC progression and evasion from the antitumor immune responses.
Like
Save
Share